Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 10, 2024Journal of Clinical Oncology

Bruton's tyrosine kinase inhibitor zanubrutinib-based regimens in relapsed/refractory primary diffuse large B-cell lymphoma of central nervous system.

View Full Paper
Ask AI
Bookmark
Share

Authors

YWYali WangNorth Sichuan Medical UniversityFCFeng ChenCapital Medical UniversityWLWenbin LiCapital Medical University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Wang et al. (2024) studied this question.

synapsesocial.com/papers/68e5cc74b6db643587563142https://doi.org/10.1200/jco.2024.42.23_suppl.30
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Zanubrutinib plus Cytarabine in Patients with Refractory/Relapsed Primary Central Nervous System Lymphoma2024 · 11 citations
  2. 2Efficacy of zanubrutinib maintenance in patients with primary CNS lymphoma achieving complete response: A phase II study2025
  3. 3Efficacy and Safety of Zanubrutinib Combined with Rituximab and High-Dose Methotrexate in the Treatment of Central Nervous System Diffuse Large B-Cell Lymphoma2025
  4. 4A real-world multicenter study of first-line zanubrutinib-based therapy for diffuse large B-cell lymphoma2026
  5. 5Phase 1 study of zanubrutinib plus lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma2026